Land: Verenigd Koninkrijk
Taal: Engels
Bron: myHealthbox
Paracetamol, Codeine Phosphate
Galen Limited
N02AA59
Paracetamol, Codeine Phosphate
30mg/500mg
Tablets
Oral use
Pack sizes: 2, 4, 6, 10, 20, 28, 30, 50, 56, 60, 84, 90, 100, 112, 120, 150, 200, 250 and 500 tablets
POM - Prescription Only Medicine
Almac Pharma Services Limited
Natural opium alkaloids
It is indicated in patients older than 12 years of age for the treatment of acute moderate pain which is not considered to be relieved by other analgesics such as paracetamol or ibuprofen (alone).
Authorised
2008-10-26
PACKAGE LEAFLET: INFORMATION FOR THE USER KAPAKE 30MG/500MG TABLETS (Codeine Phosphate and Paracetamol) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. See section 4. IN THIS LEAFLET: 1. What Kapake 30mg/500mg Tablets are and what they are used for 2. Before you take Kapake 30mg/500mg Tablets 3. How to take Kapake 30mg/500mg Tablets 4. Possible side effects 5. How to store Kapake 30mg/500mg Tablets 6. Further information 1. WHAT KAPAKE 30MG/500MG TABLETS ARE AND WHAT THEY ARE USED FOR Kapake 30mg/500mg Tablets are one of a group of medicines called analgesics or painkillers. They are used to relieve severe pain in adults. Kapake 30mg/500mg Tablets contain codeine, an opioid analgesic, in combination with paracetamol. Codeine can be used in children over 12 years of age for the short-term relief of moderate pain that is not relieved by other painkillers such as paracetamol or ibuprofen alone. 2. BEFORE YOU TAKE KAPAKE 30MG/500MG TABLETS DO NOT TAKE KAPAKE 30MG/500MG TABLETS IF YOU - are allergic (hypersensitive) to codeine phosphate, paracetamol or any of the other ingredients in Kapake 30mg/500mg Tablets (for a full list of ingredients see Section 6). - have suffered a head injury or have raised pressure in the skull (may cause painful eyes, changes in vision or headache be Lees het volledige document
Kapake 30mg/500mg Tablets. Summary of Product Characteristics Updated 05Aug2015 | Galen Limited 1. Name of the medicinal product Kapake 30mg/500mg Tablets. 2. Qualitative and quantitative composition mg per tablet Paracetamol 500.0mg (as Paracetamol DC 96% and Povidone 4%) Codeine Phosphate 30.0mg For a full list of excipients, see section 6.1. 3. Pharmaceutical form Tablet. Oblong white uncoated tablets marked 'Kapake' and bearing a scoreline on one side, the other side is plain and unmarked. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. Clinical particulars 4.1 Therapeutic indications In the treatment of severe pain in adults. Codeine is indicated in patients older than 12 years of age for the treatment of acute moderate pain which is not considered to be relieved by other analgesics such as paracetamol or ibuprofen (alone). . 4.2 Posology and method of administration For oral administration. Adults: One or two tablets to be taken every four hours as required up to a maximum of eight tablets in any 24 hour period. Paediatric population: Children aged 12 and over: One tablet to be taken every six hours as required, up to a maximum of four tablets in any 24hour period. Children aged less than 12 years: Codeine should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see sections 4.3 and 4.4). Elderly: The dosage may need to be reduced and should be titrated to the individual's need and overall medical condition. The duration of treatment should be limited to three days and if no effective pain relief is achieved the patients/carers should be advised to seek the views of a physi Lees het volledige document